MGC Pharmaceuticals Ltd (MXC)

Sydney
Currency in AUD
Disclaimer
0.006
0.000
(0.00%)
Closed
Trading near 52-week Low
Day's Range
0.006
0.006
52 wk Range
0.006
0.024
Volume
197,214
Bid/Ask
0.006 / 0.007
Prev. Close
0.006
Open
0.006
Day's Range
0.006-0.006
52 wk Range
0.006-0.024
Volume
197,214
Average Volume (3m)
2,984,080
1-Year Change
-70%
Shares Outstanding
3,349,692,950
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More

MGC Pharmaceuticals Ltd News

MGC Pharmaceuticals Ltd Analysis

MGC Pharmaceuticals Ltd Company Profile

MGC Pharmaceuticals Ltd is an Australia-based biopharma company. The Company is primarily focused on the development and supply of standardized phytomedicines to patients globally. It has three clinical projects, as well as a pipeline of therapies: CimetrA, a Phase III symptomatic treatment for early COVID-19; CannEpil, a Phase IIb cannabis-based therapy for drug-resistant Epilepsy; CogniCann, in a Phase II trial for symptomatic relief of Dementia, and Irnican, a preclinical medicine to be used for treatment for Glioblastoma. The Company is focused on the ArtemiC range of products, and its cannabinoid products are primarily distributed within Australia, the United Kingdom and South America. It has a product offering targeting two medical conditions, which include epilepsy and dementia. The Company's wholly owned subsidiaries include MGC Pharma (UK) Limited, MGC Research (Aus) Pty Ltd, and Medicinal Cannabis Clinics Pty Ltd.

Employees
0
Market
Australia